FDA Reproductive Health Drugs Cmte. returns
FDA's Reproductive Health Drugs Adivisory Committee will break a three year hiatus with a Sept. 29 meeting on clinical trial design issues and outcome measures for drugs seeking indications for induction of ovulation and pregnancy in anovulatory infertile women and development of multiple follicles in pregnancy in ovulatory women participating in assisted reproductive technology programs. It is the first meeting of the committee since Sept. 12, 2000, and since its reconstitution with new members in December 2002 (1"The Pink Sheet" Jan. 6, 2003, p. 15)...
You may also be interested in...
The new roster of FDA's Reproductive Health Drugs Advisory Committee includes two members who have conducted research or educational activities on hormone replacement therapy sponsored by Wyeth
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.